       Document 1019
 DOCN  M9621019
 TI    Membrane-interactive phospholipids inhibit HIV type 1-induced cell
       fusion and surface gp160/gp120 binding to monoclonal antibody.
 DT    9602
 AU    Krugner-Higby L; Goff D; Edwards T; Iyer N; Neufeld J; Kute T;
       Morris-Natschke S; Ishaq K; Piantadosi C; Kucera LS; Department of
       Comparative Medicine, Wake Forest University; Medical Center,
       Winston-Salem, North Carolina 27157-1064, USA.
 SO    AIDS Res Hum Retroviruses. 1995 Jun;11(6):705-12. Unique Identifier :
       AIDSLINE MED/96078231
 AB    Membrane-interactive phospholipids (PLs), previously evaluated for
       activity against HIV-1 in vitro, are known to affect late steps in viral
       replication. Studies were done to determine the effects of PL analogs on
       post-translational processing of HIV-1 proteins, binding of viral
       surface gp160/gp120 to CD4 receptor, and HIV-1-induced cell fusion.
       Results of this investigation indicated that PL alone
       (1-octadecanamido-2-ethoxypropyl-rac-3-phosphocholine, CP-51) and PL-AZT
       conjugate (1-octadecanamido-2-ethoxypropyl-rac-3-phospho-3'-
       azido-3'-deoxythymidine, CP-92) have no effect on HIV-1-induced
       syntheses or processing of gp160/gp120, pr51, p24, or p17 (including
       myristoylation) in infected cells. Progeny HIV-1 particles made in
       CP-92-treated H9IIIB cells contained gp120, pr51, and p24; however,
       these virus particles had reduced capacity to bind to CD4+ cells. Both
       CP-51 and CP-92 inhibited syncytium (cell fusion) formation between
       treated HIV-1-infected cells and uninfected CD4+ cells, and, they
       reduced HIV-1 gp160/gp120 binding to CD4+ cells and monoclonal antibody.
       These results suggest that anti-HIV-1 activity of PL compounds involves
       alteration of cell surface membranes and viral envelopes. Phospholipid
       compounds are a novel class of membrane interactive compounds with
       potential use in blocking the spread of HIV-1 infection and pathogenesis
       in AIDS.
 DE    Antibodies, Monoclonal/METABOLISM  Cell Fusion/*DRUG EFFECTS  Cell
       Membrane/DRUG EFFECTS/VIROLOGY  CD4-Positive T-Lymphocytes/VIROLOGY
       Gene Products, env/*METABOLISM  HIV Antibodies/METABOLISM  HIV Envelope
       Protein gp120/*METABOLISM  HIV-1/*DRUG EFFECTS  Indolizines/PHARMACOLOGY
       Myristic Acids/METABOLISM  Phospholipid Ethers/CHEMICAL
       SYNTHESIS/PHARMACOLOGY  Phospholipids/CHEMICAL SYNTHESIS/*PHARMACOLOGY
       Protein Precursors/*METABOLISM  Protein Processing,
       Post-Translational/DRUG EFFECTS  Support, U.S. Gov't, P.H.S.  Viral
       Proteins/BIOSYNTHESIS/METABOLISM  Virion/METABOLISM  Zidovudine/ANALOGS
       & DERIVATIVES/CHEMICAL SYNTHESIS/PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

